Core Insights - Dyadic International, Inc. has achieved significant milestone payments in collaborations with Proliant Health & Biologicals and Inzymes ApS, indicating progress in its business transformation and commercial initiatives [1][2] Group 1: Company Developments - Dyadic is transitioning to a commercially focused, revenue-driven company, with substantial progress noted in Q3 2025 across its portfolio [2] - The company is committed to capitalizing on near-term commercialization opportunities, supported by a stronger balance sheet and an expanding pipeline of products [2] Group 2: Life Sciences - Dyadic reached a $500,000 milestone in its partnership with Proliant for Recombinant Human Albumin, with commercialization expected to advance in late 2025 to early 2026 [7] - The company is expanding sampling efforts for Recombinant Transferrin in research, diagnostics, and cultured meat markets, with initial production underway [7] - Dyadic's Recombinant DNase I has met performance benchmarks, validating its utility in molecular biology and diagnostics, with production at research grade ongoing [7] Group 3: Food & Nutrition - A term sheet has been signed for the development of non-animal human alpha-lactalbumin for the infant nutrition market, with initial sampling in progress [7] - Dyadic received a $250,000 milestone payment from Inzymes for non-animal dairy enzymes, with the first enzyme's scale-up on track for a late 2025 launch [7]